There is mounting evidence that combining MSCs and IL10 protein therapy can reduce inflammation in a variety of diseases, including experimental autoimmune encephalomyelitis [57], spinal cord injury [31] and ischemia–reperfusion injury [58]. This evidence concerns the gene IL10 and experimental autoimmune encephalomyelitis.